← all works
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian funderA Canadian agency funded it. The work may carry no Canadian affiliation at all.
No Canadian affiliation. An affiliation-only frame — the usual design — would never have seen this work. It is one of the works that make the case for inverting the frame.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- The Lancet
- Topic
- Blood Pressure and Hypertension Studies
- Field
- Medicine
- Canadian institutions
- —
- Funders
- Canadian Institutes of Health ResearchHeart and Stroke Foundation of CanadaBoehringer Ingelheim
- Keywords
- TelmisartanMedicinePlaceboStroke (engine)Hazard ratioInternal medicineMyocardial infarctionDiabetes mellitusHeart failureBlood pressureAngiotensin receptorRandomized controlled trialCardiologyAngiotensin IIConfidence intervalEndocrinology
- Has abstract in OpenAlex
- no